Mining predictive biomarker for neoadjuvant chemotherapy in gastric cancer by proteomics

Hepato-Gastroenterology

Volumn 58, Issue 110-111, 2011, Pages 1828-1833

  Qian, Jiajie ^a   Li, Fuqiang ^a   Yu, Jiren ^a   Yang, Zili ^a   Chen, Jing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gastric cancer; Proteomics; SELDI TOF MS

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; STOMACH CANCER; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE SECTION; TREATMENT RESPONSE;

EID: 83355174164     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11047     Document Type: Article

References (37)

1. Yamaoka Y, Kato M, Asaka M: Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 2008; 47:1077-1083.
2. Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM: Association of H. pylori infection with gastric carcinoma: a Meta analysis. World J Gastroenterol 2001; 7:801-804. (Pubitemid 34051497)
3. Roukos DH: Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000; 26:243-255.
4. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21:3357-3365. (Pubitemid 46606270)
5. Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379-392. (Pubitemid 38101633)
6. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7:1318-1326. (Pubitemid 19220135)
7. Brenner B, Shah MA, Karpeh MS, Gonen M, Brennen MF, Coit DG, Klimstra DS, Tang LH, Kelsen DP: A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol 2006; 17:1404-1411. (Pubitemid 44403435)
8. Roukos DH: Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999; 6:46-56.
9. Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U: Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003; 6:159-167. (Pubitemid 37221566)
10. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL: Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Can Oncol 2004; 22:2774-2780. (Pubitemid 41079894)
11. Engwegen JY, Gast MC, Schellens JH, Beijnen JH: Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006; 27:251-259.
12. Hanash SM: Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis 2000; 21:1202-1209.
13. Emmert-Buck MR, Gillespie JW, Paweletz CP, Ornstein DK, Basrur V, Appella E, Wang QH, Huang J, Hu N, Taylor P, Petricoin EF 3rd: An approach to proteomic analysis of human tumors. Mol Carcinog 2000; 27:158-165. (Pubitemid 30149311)
14. Bi X, Lin Q, Foo TW, Joshi S, You T, Shen HM, Ong CN, Cheah PY, Eu KW, Hew CL: Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Mol Cell Proteomics 2006; 5:1119-1130. (Pubitemid 43985935)
15. Hanash S: Disease proteomics. Nature 2003; 422:226-232.
16. Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003; 3:267-275. (Pubitemid 37328862)
17. Bitarte N, Bandrés E, Zárate R, Ramirez N, Garcia-Foncillas J: Moving forward in colorectal cancer research, what proteomics has to tell. World J Gastroenterol 2007; 13:5813-5821. (Pubitemid 350148498)
18. Cowan ML, Vera J: Proteomics: advances in biomarker discovery. Expert Rev Proteomics 2008; 5:21-23. (Pubitemid 351287738)
19. Wang KJ, Wang RT, Zhang JZ: Identification of tumor markers using two-dimensional electrophoresis in gastric carcinoma. World J Gastroenterol 2004; 10:2179-2183.
20. Ryu JW, Kim HJ, Lee YS, Myong NH, Hwang CH, Lee GS, Yom HC: The proteomics approach to find biomarkers in gastric cancer. J Korean Med Sci 2003; 18:505-509. (Pubitemid 38030517)
21. Wu C, Luo Z, Chen X, Wu C, Yao D, Zhao P, Liu L, Shi B, Zhu L: Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. Oncol Rep 2009; 21:1429-1437.
22. Lu X, Zhu H: Tube-gel digestion: a novel proteomic approach for high throughput analysis of membrane proteins. Mol Cell Proteomics 2005;4:1948-1958. (Pubitemid 41830189)
23. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr, Wright GL Jr, Semmes OJ: Serum protein profiles to identify head and neck cancer. Clin Cancer Res 2004; 10:1625-1632. (Pubitemid 38435552)
24. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, Chan DW, Canto M, Lillemoe KD, Cameron JL, Yeo CJ, Hruban RH, Goggins M: Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002; 62:1868-1875. (Pubitemid 34408515)
25. Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF, Semmes OJ, Wright GL Jr: Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002; 8:2541-2552. (Pubitemid 34856338)
26. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M: Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10:860-868. (Pubitemid 38198884)
27. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577. (Pubitemid 34178440)
28. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62:3609-3614. (Pubitemid 34728833)
29. de Noo ME, Tollenaar RA, Deelder AM, Bouwman LH: Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J Gastroenterol 2006; 12:6594-6601. (Pubitemid 44794934)
30. Ward DG, Nyangoma S, Joy H, Hamilton E, Wei W, Tselepis C, Steven N, Wakelam MJ, Johnson PJ, Ismail T, Martin A: Proteomic profiling of urine for the detection of colon cancer. Proteome Sci 2008; 6:19.
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
32. Neubauer H, Stefanova M, Solomayer E, Meisner C, Zwirner M, Wallwiener D, Fehm T: Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res 2008; 28:949-955. (Pubitemid 351578941)
33. Lindskog M, Spenger C, Jarvet J, Gräslund A, Kogner P: Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma. J Natl Cancer Inst 2004; 96:1457-1466. (Pubitemid 39429670)
34. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15:68-74.
35. Celis JE, Gromov P, Cabezón T, Moreira JM, Ambartsumian N, Sandelin K, Rank F, Gromova I: Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 2004; 3:327-344. (Pubitemid 38702087)
36. Kulasingam V, Diamandis EP: Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics 2007; 6:1997-2011. (Pubitemid 350201873)
37. Chien J, Wong E, Nikes E, Noble MJ, Pantazis CG, Shah GV: Constitutive activation of stimulatory guanine nucleotide binding protein (G(S)alphaQL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene 1999; 18:3376-3382. (Pubitemid 29286983)